Recent

% | $
Quotes you view appear here for quick access.

The Advisory Board Company Message Board

thekindaguyiyam 48 posts  |  Last Activity: Apr 17, 2015 7:36 PM Member since: Jun 7, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • thekindaguyiyam thekindaguyiyam Apr 17, 2015 7:36 PM Flag

    enrtdya133
    6 posts | Last Activity: 10 minutes ago
    Member since: Apr 17, 2015

    please. are you an intentional noise maker or are you on drugs?
    IggyZone material if ever I've read it.

    Sentiment: Strong Buy

  • Reply to

    #CramerOnAfrezza

    by apomyster Apr 8, 2015 3:32 PM
    thekindaguyiyam thekindaguyiyam Apr 8, 2015 4:43 PM Flag

    it's stupid to those who know. it isn't stupid to cramer who is an admitted short interest stock manipulator. not stupid; dishonest manipulation.

    Sentiment: Strong Buy

  • Reply to

    PLEASE Put this ID cloning CLOWN on IGNORE!

    by mann.ontop2 Apr 8, 2015 2:04 PM
    thekindaguyiyam thekindaguyiyam Apr 8, 2015 3:06 PM Flag

    done. So easy; it was just like flushing the toilet. Another fake sent to the sewer from where he came. If a basher can't even be his "own" identity what would that tell anyone regarding authenticity and truth.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Apr 7, 2015 12:48 PM Flag

    just to play the devil advocate in reply to your post. Not so! Pfizer, J&J, Lilly, Novolog and more;
    ALL Hate Afrezza. This is a good thing.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Apr 3, 2015 2:21 PM Flag

    Good post.
    We have a research and development company with new products which are based on the Technosphere Platform. Afrezza is the first test product. I think that's why they took such a small percentage with Sonofi to be sure it could sustain delivery against huge competition. I see This as a paradigm shift of paramount importance. All data is guarded and released with the greatest discretion as decided by management for the Company's Security in the presence of competitive Giants (Phizer, Lilly etc.) that don't want to lose Billions in revenue as a result of Technosphere.

    I'm in the company in part because Alfred is "The" Innovator in the Science of Diabetes. He is 89 years old, Savy as hell, cunning, successful in other significant corporatiions and his money goes to his philanthropic enterprises. If am surrendering my investment to a founder and company that have everything seemingly in the works; how can I do better than this?

    I am a voyeur in the decision making process; though I do speak up when addressing issues questioning the integrity of management from an entitlement attitude. As if one's investment in this prospect makes them an armchair CEO.

    I like what you have to say. Keep on posting and Thanks for your contribution.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Apr 3, 2015 2:01 PM Flag

    I'm curious Kevin. Do you think that your opinions affect MNKD Management decisions? thanks in advance.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Apr 2, 2015 4:52 PM Flag

    In agreement. Well said. Thanks.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Apr 2, 2015 4:51 PM Flag

    excellent post as it educates and gives balance to some of the moronic bs posted here. inspiring enough for me to read some of your past posts. Thanks and please continue.

    Sentiment: Strong Buy

  • Reply to

    The Future will be..

    by itellthefuture777 Mar 28, 2015 12:34 PM
    thekindaguyiyam thekindaguyiyam Apr 2, 2015 4:35 PM Flag

    You are an excellent source of information. Have you taken a look at the pro board?

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Apr 2, 2015 3:38 PM Flag

    amusingly stated. thanks. very zen of you.

    Sentiment: Strong Buy

  • Reply to

    I'M LONG BUT LETS FACE IT...........REALLY

    by izmatic01 Apr 1, 2015 7:01 PM
    thekindaguyiyam thekindaguyiyam Apr 2, 2015 3:35 PM Flag

    You don't speak for me. You may consider yourself a loser while holding shares of a company that may very well shift the medical world and it's population. It is your expectation of what you think it should be disregarding organized crime of short interest. 90 million shares being shorted in conjunction with BS articles written by Cramer's "the Steet", Cramer's imbecile adam fraeurstein etc. Two markets here. One the stock market full of those who see any company as a commodity to steal from and the other one that is science, medicine and a patient base which is 1/3 of the world's population.

    What do I expect? I expect it will take the time it takes. What do I believe? I believe that Technosphere will largely replace needles in the application of faster and better medications provided to mankind from Alfred Mann's Mannkind.

    Sounds like your expectations weren't met. I thought we'd be further along as well at this point, but when you have huge wealth to be made and you are rational you recognize that there are pirates who are willing to kill this company, it's meds and diabetics around the world to make a buck. With that, I have adjusted my time frame for this to happen when science can no longer be disputed by some hyped BS from AF & Jim Cramer.

    Sentiment: Strong Buy

  • Reply to

    Prnt ads for Toujeo

    by papa_tutu Apr 2, 2015 12:15 AM
    thekindaguyiyam thekindaguyiyam Apr 2, 2015 12:43 AM Flag

    well... in 2007 mnkd hadn't brought Afrezza to market. Few people knew what Technosphere was and it's potential paradigm shift. With catalysts of distribution in the UK and the EU and probably Canada... the manipulation by hedge funds that provide the utter bs of cramer and freurstein won't be able to keep up with social media of patients to other patients and then there doctors by demand. So Danbury is producing 24/7
    with 2 more lines coming on in the 2nd quarter of this year. Isn't it a bit of supply being able to meet the demand? Therefore, advertising before the meds are more readily available would be a marketing nightmare to create more market than can be supplied. It will take a little time for the supply to meet the demand; until then advertising would be counter productive.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Apr 1, 2015 2:41 PM Flag

    you accuse someone who says they are a doctor as being fraudulent referring to them as a loser. Here you are shortie pretending to be one of the greatest scientists in medicine... what does that make you? An #$%$!
    You offer nothing of worth.. you are worthless stock manipulator who thinks your words carry any influence.
    Welcome to the IGGY ZONE.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Mar 30, 2015 2:19 PM Flag

    last page by Robert Sacher
    Robert's last page of article:

    "Although less common than in type 1 diabetes, the frequency of hypoglycemia in insulin-treated type 2 diabetes progressively rises with increasing duration of insulin treatment."

    And they close with,

    "In insulin-treated type 2 diabetes, the frequency of hypoglycemia must not be underestimated, particularly in the elderly, in whom the morbidity of hypoglycemia poses particular problems, and the mortality may be unrecognized."

    Afrezza could prove to be highly profitable for Sanofi and MannKind if what early adopters are discovering for themselves is indeed true for the majority of other diabetics. If diabetics believe that Afrezza greatly reduces your risk of having a hypoglycemic event, it may not matter if that wording actually appears on the label, not in this age of social media and instantaneous communication. What may matter is what works best and what is discovered through word of mouth, especially for those who live with this issue every day.

    Naysayers will point to the fact that there is no message on the Afrezza label pointing to decreased risk of hypoglycemia and therefore, if it is truly the case that Afrezza reduces hypoglycemic risk, doctors will not prescribe it in any event. But, that will remain to be seen, especially if the issue affects almost half of the population of diabetics. And, it could always be the case that the FDA will allow a change in the label at some point in the future if follow-up studies eventually statistically prove what early adapters are finding to be true.

    So, while the market is focused on Lantus and what will become of Toujeo, MannKind's Afrezza inhaled insulin may turn out to be the goose that lays the golden egg for both Sanofi and MannKind Corporation.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Mar 30, 2015 2:11 PM Flag

    Robert Sacher
    Long only, growth, long-term horizon, medium-term horizon
    Profile| Send Message| Follow (80 followers)
    Afrezza Could Be Sanofi And MannKind's Goose That Laid The Golden Egg
    Mar. 30, 2015 1:48 PM ET | 2 comments | About: MannKind Corporation (MNKD), Includes: SNY
    Disclosure: The author is long "MNKD". (More...)
    Summary
    As Lantus nears patent expiration, Afrezza could be very helpful if Toujeo falters in dominating new market share.
    Early adopters reporting Afrezza less likely to cause hypoglycemic events.
    Afrezza could win large foothold in type 1 diabetes treatment quickly as type 2 develops.
    This article was sent to 17,923 people who get email alerts on MNKD.
    Get email alerts on MNKD »
    According to a short article published by Reuters last Friday, French drugmaker, Sanofi (NYSE:SNY), plans to launch its new Toujeo insulin for diabetics in the United States today. Approved by the FDA on February 25th, Toujeo is basal insulin taken once per day for excessive blood glucose in both type 1 and type 2 diabetes therapy.

    Clinical studies successfully met criteria designed to show that Toujeo would have similar blood glucose control results as Lantus, the current dominant basal insulin which grossed over seven billion dollars last year. However, due to the impending patent expiration on Lantus coming next year and the inevitable generic choices which will lower prices and profits, Sanofi is hoping for and designing a way to move customers who have been on Lantus over to Toujeo. Towards that end, Toujeo clinical studies have shown that Toujeo carries less risk of hypoglycemia, a potential life threatening blood sugar drop, compared with Lantus, particularly at night. However, it may be that most patients will either stay on Lantus or move to a generic version because the FDA label for Toujeo does not include information on night-time hypoglycemia.

    continues

    Sentiment: Strong Buy

  • Reply to

    Amy Tenderich review of Afrezza on Twitter

    by dtrouble1003 Mar 30, 2015 10:38 AM
    thekindaguyiyam thekindaguyiyam Mar 30, 2015 10:58 AM Flag

    you are correct. I mixed it up with another poster. As for amy: google this Test Driving New Inhaled Insulin Afrezza Written by Amy Tenderich | Published on March 30, 2015

    Sentiment: Strong Buy

  • Reply to

    Amy Tenderich review of Afrezza on Twitter

    by dtrouble1003 Mar 30, 2015 10:38 AM
    thekindaguyiyam thekindaguyiyam Mar 30, 2015 10:45 AM Flag

    Thank You. This is an excellent video from someone who is a diabetic who uses Afrezza and has the attention of many Diabetics who are trying to figure it out. In this Video she addresses the variable of her reactions to Afrezza. Nothing like first hand accounts from reliable sources.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Mar 30, 2015 10:17 AM Flag

    spam = ignore

  • thekindaguyiyam thekindaguyiyam Mar 28, 2015 11:12 PM Flag

    Hey!

    I've seen some of the fringe element post there. You want more? Gotta laugh.

    Sentiment: Strong Buy

  • Reply to

    AF is a creep!

    by yumpingsven Mar 27, 2015 3:58 PM
    thekindaguyiyam thekindaguyiyam Mar 27, 2015 4:45 PM Flag

    He's more than a Creep; He's a Criminal who works for the Criminal Jim Cramer. They should both be in prison.
    ADAM FEUERSTEIN
    “Anyone who reads the [U.S. Army Medical Research Institute of Infectious Disease] report can see Feuerstein is wrong. This is blatant short mongering at its worst. Feuerstein's defamation of these results hurst not only the company's stockholders; it impedes development of an important experimental therapeutic that could save thousands of lives in West Africa.”
    – Thomas K. Equels, Hemispherx' Executive Vice Chairman, in press release (02.09.15)
    “In theory, short-selling enhances the efficiency of markets by bringing in fresh information and capital. In reality, it has contributed to turning financial markets into a giant casino which is easily rigged for the benefit of insiders."
    – Steven Pearlstein, Washington Post columnist, in Washington Post article on Feuerstein (09.27.14)
    “When several drug companies repeatedly see big stock price dips due to a negative articles published at critical moments — especially when those dips benefit the financial interests of short sellers — it should raise serious questions at the SEC. Given the suspicious timing of Mr. Feuerstein’s articles, which include misinformation and innuendo, there should be an inquiry into whether there was a deliberate effort to manipulate the market for profit.”
    – CREW’s former Executive Director Melanie Sloan in press release (07.29.14)
    “In our field, sentiment affects stock price, and even one negative comment that seems informed, whether or not it really is informed, can have an impact.”
    – Mark Saad, Cytori’s former Chief Financial Officer, in Bloomberg Businessweek (04.17.14)
    “The reason that I have gone to great lengths in this note to critique Mr. Feuerstein's comments is that they were made with no discernible effort at fairness and balance. I think that authors who are advising investors have an obligation to present both the negatives and positives of an investment.

    Sentiment: Strong Buy

ABCO
52.31-1.26(-2.35%)Apr 17 4:00 PMEDT